Santonin helps reverse the brain changes and behavior problems caused by AlCl 3 in rats, and it looks promising as a neuroprotective agent for AD.
Abstract
Alzheimer’s disease (AD) is one of the neurodegenerative diseases that is marked by deterioration in cognitive functioning and behavioral capacities in a progressive manner. It is the most prevalent cause of dementia in the aging population and imposes a high social and economic cost on the global population.
In this study, we have examined Santonin, which can prevent the brain damage caused by aluminum chloride (AlCl
3
) in rats, a typical method used to simulate the effects of AD in the laboratory.
We administered AlCl
3
(100 mg/kg) to the rats to induce changes in them that resembled Alzheimer’s and tested their behavior using the open field and elevated plus maze tests. Then, we analyzed their brains in terms of the presence of inflammation, oxidative stress, enzyme activities, and tissue damage.
The rats receiving AlCl
3
had reduced motility and an increase in acetylcholinesterase, malondialdehyde, and inflammatory cytokines, including cyclooxygenase-2, tumor necrosis factor-alpha, and interleukin-6. Their antioxidant defense mechanisms, glutathione, superoxide dismutase, and catalase, also decreased. However, these effects were changed positively when we treated rats with Santonin. Their movement was better, and they responded quicker, and their brains became less inflamed and less oxidatively stressed. Santonin reduced levels of harmful proteins and enzymes and restored antioxidant activity in a dose-dependent manner.
Santonin helps reverse the brain changes and behavior problems caused by AlCl
3
in rats. It looks promising as a neuroprotective agent for AD.
Alzheimer's disease (AD), a progressive neurodegenerative disorder, characterized by the deposition of amyloid-β plaques in the hippocampus, leading to cognitive and behavioral impairments. This study investigated the neuroprotective outcome of Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor primarily...
Lovekesh Singh, G. Das Gupta, Shamsher Singh· Assay and drug development t...· 0 citations
ZIN protects against D-galactose-induced cognitive and motor deficits by enhancing antioxidant and anti-inflammatory activity in the hippocampus and attenuate histopathological changes in the cortex and hippocampal areas of D-gal-induced brain aging rats.
A. Malayeri, Mohsen Zand, Sirous Rafiei Asl et al.· Molecular Biology Reports· 0 citations
Background: Effective drugs for the prevention and treatment of Alzheimer's disease (AD) remain scarce. Antioxidant compounds are increasingly being explored for their anti-Alzheimer’s potential. This has led to the inclusion of up to three compounds in the 2023 Alzheimer's drug development pipeline for phase 3 trials...
Injoh Nicoline Agwe, B. Azantsa, Nikanor Rudig Tadah Djikem et al.· Journal of Drug Delivery and...· 0 citations
ETHNOPHARMACOLOGICAL RELEVANCE
Alzheimer's disease (AD) is one of the leading causes of cognitive impairment and dementia among the elderly and has become an urgent public health challenge due to population ageing. Du-Shu-Wan (DSW) is an ancient Chinese herbal medicine that aims to enhance memory and soothe the spirit,...
Shang-Zhi Liu, Li-Song Ren, Ling Liu et al.· Journal of Ethnopharmacology· 0 citations
The symptoms of Alzheimer's disease (AD), a neurodegenerative disease that worsens over time, include oxidative stress, neuronal death, and failure of the cholinergic system. The present investigation set out to evaluate, in Alzheimer's disease animal models, the neuroprotective efficacy of novel drug candidates. Five...
Anjali Gupta· Natural Resources for Human...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.